Characterization of the kynurenine pathway in NSC‐34 cell line: implications for amyotrophic lateral sclerosis
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
J. Neurochem.(2011)118, 816–825. Amyotrophic lateral sclerosis (ALS) is the most common type of motor neuron degenerative disease for which the aetiology is still unknown. The kynurenine pathway (KP) is a major degradative pathway of tryptophan ultimately leading to the production of NAD+and is also one of the major regulatory mechanisms of the immune response. The KP is known to be involved in several neuroinflammatory disorders. Among the KP intermediates, quinolinic acid (QUIN) is a potent excitotoxin, while kynurenic acid and picolinic acid are both neuroprotectant. This study aimed to (i) characterize the components of the KP in NSC‐34 cells (a rodent motor neuron cell line) and (ii) assess the effects of QUIN on the same cells. RT‐PCR and immunocytochemistry were used to characterize the KP enzymes, and lactate dehydrogenase (LDH) test was used to assess the effect of QUIN in the absence and presence of NMDA receptor antagonists, kynurenines and 1‐methyl tryptophan. Our data demonstrate that a functional KP is present in NSC‐34 cells. LDH tests showed that (i) QUIN toxicity on NSC‐34 cells increases with time and concentration; (ii) NMDA antagonists, 2‐amino‐5‐phosphonopentanoic acid, MK‐801 and memantine, can partially decrease QUIN toxicity; (iii) kynurenic acid can decrease LDH release in a linear manner, whereas picolinic acid does the same but non‐linearly; and (iv) 1‐methyl tryptophan is effective in decreasing QUIN release by the rodent microglial cell line BV‐2 and thus protects NSC‐34 from cell death. There is currently a lack of effective treatment for ALS and our in vitro results provide a novel therapeutic strategy for ALS patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751
Guillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497
Self-citationInflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470
The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons
Rahman, A., Ting, K., Cullen, K. M., Braidy, N., Brew, B. J., & Guillemin, G. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006344 · Cited by 257
Self-citationThe kynurenine pathway and inflammation in amyotrophic lateral sclerosis
Chen, Y., Stankovic, R., Cullen, K. M., Meininger, V., Garner, B., Coggan, S., Grant, R., Brew, B. J., & Guillemin, G. J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-009-9129-7 · Cited by 141
Self-citationDevelopment and characterisation of a glutamate-sensitive motor neurone cell line
Eggett, C. J., Crosier, S., Manning, P., Cookson, M. R., Menzies, F. M., McNeil, C. J., & Shaw, P. J. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741895.x · Cited by 111 · cited 2×
“The differentiated cells were maintained in reduced-serum medium and passaged twice without loss of viability (Eggett et al. 2000).”
BackgroundMethodGuillemin, G. J., Smith, D. G., Kerr, S. J., Smythe, G. A., Kapoor, V., Armati, P. J., & Brew, B. J. (2000) · Redox Report · doi:10.1179/135100000101535375 · Cited by 108
Self-citationImplications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis
Guillemin, G. J., Meininger, V., & Brew, B. J. (2005) · Neurodegenerative Diseases · doi:10.1159/000089622 · Cited by 105
Self-citation
Cited by
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Quinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Self-citationThe kynurenine pathway and the brain: Challenges, controversies and promises
Schwarcz, R., & Stone, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.08.003 · Cited by 461
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Self-citationQuinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394
Metadata
- Authors
- Chen, Y., Brew, B. J., & Guillemin, G. J.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2011-01-28
- Volume
- 118
- Issue
- 5
- Pages
- 816-825
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1603819614
- Cited by
- 68
- References
- 8
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of the kynurenine pathway in NSC‐34 cell line: implications for amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1111/j.1471-4159.2010.07159.x
- The paper
- Chen, Y., Brew, B. J., & Guillemin, G. J. (2011). Characterization of the kynurenine pathway in NSC‐34 cell line: implications for amyotrophic lateral sclerosis. Journal of Neurochemistry. https://doi.org/10.1111/j.1471-4159.2010.07159.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.